Pfizer's Lipitor-Torcetrapib Phase II Results Show HDL-LDL Double-Punch

Combination therapy trial reveals HDL-C increases of 61% for the drugs used together and 46% for torcetrapib alone. Pfizer is understood to be investing $800 mil. in the drug's development, including a $90 mil. manufacturing facility.